Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Peringkat dalam Saham #41418
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Harga Saham
$0.0001
Terakhir disinkronkan: 2025-06-11
Kapitalisasi Pasar
$21.52K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Diagnocure, Inc. (DGCRF)

Kategori

Laba untuk Diagnocure, Inc. (DGCRF)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Diagnocure, Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Diagnocure, Inc. dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing